Seth J. Orlow

Easton Capital Investment Group (Easton) is a Venture Capital firm which is founded in 2000 by John H. Friedman. The firm is headquartered in New York ,US.

Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA.

Coapt Systems, Inc. designs, develops, manufactures and markets bio absorbable implants for surgeons to use in plastic surgery to fixate soft tissue to other soft tissue and bone. The company was founded in 2000 and is headquartered in Palo Alto, CA.

Ivrea Pharmaceuticals, Inc. develops pharmaceuticals for dermatologic conditions. The company's clinical trials include IVR 101/102 and IVR 103. Ivrea Pharmaceuticals was founded by Maurizio V. Cattaneo in May 2005 and is headquartered in Quincy, MA.

Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals.